Trials / Completed
CompletedNCT03389984
Psoriatic Inflammation Markers Predictive of Response to Adalimumab
Characterization of the Initial Psoriatic Skin Transcriptionnl Profile Associated to a Response to Adalimumab Therapy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to compare the initial skin inflammatory transcriptomic profile of psoriatic patient responder to Adalimumab therapy (defined as the achievement of a Psoriasis Area and Severity Index 75 response at 16 weeks) with the transcriptomic profile of patient non-responder to Adalimumab therapy (defined as the non-achievement of a Psoriasis Area and Severity Index 50 response at 16 weeks) to identify differentially expressed genes in order to define predictive markers of response to the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | cutaneous | SKIN BIOPSY |
Timeline
- Start date
- 2017-11-14
- Primary completion
- 2019-11-30
- Completion
- 2020-06-18
- First posted
- 2018-01-04
- Last updated
- 2020-09-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03389984. Inclusion in this directory is not an endorsement.